Last year, BCAN and its partners shared a message regarding the global shortage of Merck’s TICE BCG due to an increasing global demand for the product.
Merck, the sole manufacturer globally since 2012, approved plans to construct a new manufacturing facility to significantly expand production capacity for TICE® BCG (BCG Live For Intravesical Use), a medicine for the treatment of certain forms of bladder cancer. While this commitment is an important step in making sure that an adequate supply of TICE BCG is available, completing the construction of a manufacturing facility may take approximately 5 to 6 years. Read the message from Merck here.
The American Urological Association (AUA), American Association of Clinical Urologists (AACU), Bladder Cancer Advocacy Network (BCAN), Society of Urologic Oncology (SUO), the Large Urology Group Practice Association (LUGPA) and the Urology Care Foundation (UCF) remain extremely concerned about this ongoing shortage and its effects on the care of bladder cancer patients.